New oral anticoagulants: A review of the literature with particular emphasis on patients with impaired renal function

Drugs

Volumn 72, Issue 13, 2012, Pages 1739-1753

  Poulsen, Birgitte Klindt ^a   Grove, Erik Lerkevang ^a   Husted, Steen Elkjaer ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

Author keywords

Anticoagulants; Apixaban; Betrixaban; Dabigatran etexilate; Edoxaban; Oral; Pharmacology; Renal impairment; Rivaroxaban; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APIXABAN; BETRIXABAN; DABIGATRAN ETEXILATE; DILTIAZEM; EDOXABAN; ENOXAPARIN; KETOCONAZOLE; NAPROXEN; RIFAMPICIN; RITONAVIR; RIVAROXABAN; VERAPAMIL; WARFARIN;

BLEEDING; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; EMBOLISM; FOOD; FOOD DRUG INTERACTION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DYSFUNCTION; LUNG EMBOLISM; REVIEW; SINGLE DRUG DOSE; STROKE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; METABOLIC DETOXICATION, DRUG; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84865642185     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635730-000000000-00000     Document Type: Review

References (60)

1. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009;48(1):1-22
2. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33(4):278-85 (Pubitemid 15087125)
3. Brosius III FC, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 2006;114(10):1083-7 (Pubitemid 44358886)
4. Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 2005;5(5):291-305 (Pubitemid 41306468)
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 Feb; 39 (2 Suppl. 1): S1-266
6. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. London: EMA, 2004 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003123.pdf [Accessed 2012 Aug. 9]
7. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119(10):1363-9
8. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159(6):1102-7
9. Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother 2008;6(1):1-11 (Pubitemid 351722955)
10. Samama MM. Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment. Drugs Aging 2011;28(3):177-93
11. Pavord S, Myers B. Bleeding and thrombotic complications of kidney disease. Blood Reviews 2011;25(6):271-8
12. Pisters R, Lane DA, Nieuwlaat R, et al. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100
13. Falga C, Capdevila JA, Soler S, et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency: findings from the RIETE registry. Thromb Haemost 2007;98(4):771-6 (Pubitemid 47555068)
14. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010 Feb; 137 (2):263-72
15. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12(10):1360-420
16. Cook LM, Kahn SR, Goodwin J, et al. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 2007;5(5):937-41 (Pubitemid 46691722)
17. Lee M, Saver JL, Chang KH, et al. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 2010;341:c4249
18. Di AE, Chowdhury R, Sarwar N, et al. Chronic kidney disease and risk of major cardiovascular disease and nonvascular mortality: prospective population based cohort study. BMJ 2010;341:c4986
19. Yang F, Chou D, Schweitzer P, et al. Warfarin in haemodialysis patients with atrial fibrillation: what benefit? Europace 2010;12(12):1666-72
20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
21. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. NEngl J Med 2011;364(9):806-17
22. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159(3):340-7
23. Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 10th edition. New York: McGraw-Hill, 2001
24. Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl.):e120S-51S
25. Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis 2010;29(1):92-104
26. Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitorin: against. J Thromb Haemost 2010;8(4):627-30
27. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011;49(5):761-72
28. Van RJ, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor. Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103(6):1116-27
29. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012;107(2):379-87
30. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104(6):1263-71
31. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50(7):743-53
32. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36(2):386-99 (Pubitemid 351185753)
33. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64(3):292-303 (Pubitemid 47283865)
34. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47(1):47-59 (Pubitemid 350260888)
35. Boehringer Ingelheim. Summary of product characteristics: Pradaxa 75 mg hard capsules [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000829/WC500041059.pdf [Accessed 2012 Feb. 2]
36. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9(11):2168-75
37. Troconiz IF, Tillmann C, Liesenfeld KH, et al. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007;47(3):371-82 (Pubitemid 46294714)
38. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallelgroup, single-centre study. Clin Pharmacokinet 2010;49(4):259-68
39. Dahl OE, Kurth AA, Rosencher N, et al. Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. Int Orthop 2012 Apr; 36 (4):741-8. Epub 2011 Nov. 18
40. Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 2012;52(1 Suppl.):119S-25S
41. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 2012;26(1):27-32
42. Bayer Schering Pharma. Summary of product characteristics: Xarelto 10 mg film-coated tablets [online]. Available from URL: http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf [Accessed 2012 Jan 20]
43. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010;70(5):703-12
44. Bauer KA, Homering M, Berkowitz SD. Effects of age, weight, gender and renal function in a pooled analysis of four phase III studies of rivaroxaban for prevention of venous thromboembolism after major orthopedic surgery [abstract no. 436]. Blood (ASH Annual Meeting Abstracts) 2008:166-7
45. Mueck W, Lensing AW, Agnelli G, et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50(10):675-86
46. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32(19):2387-94
47. Watson J, Whiteside G, Perry C. Apixaban: first global approval. Drugs 2011;71(15):2079-89
48. Davis EM, Packard KA, Knezevich JT, et al. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. Pharmacotherapy 2011;31(10):975-1016
49. Bristol-Myers Squibb, Pfizer. Summary of product characteristics: Eliquis 2.5 mg film-coated tablets [online]. Available from URL: http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/002148/ WC500107728.pdf [Accessed 2011 Jun. 20]
50. Leil TA, Feng Y, Zhang L, et al. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther 2010;88(3):375-82
51. Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012 Aug; 21 (6):429-35
52. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92
53. Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007;98(4):883-8 (Pubitemid 47555083)
54. Fuji T, Fujita S, Tachibana S, et al. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010;8(11):2458-68
55. Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement: a randomised double-blind dose-response study. Thromb Haemost 2010;104(3):642-9
56. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160(4):635-41
57. Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006;354(10):997-9 (Pubitemid 43357803)
58. Lip GY. Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk. Europace 2011;13(2):145-8
59. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011;57(12):1339-48
60. Davison AM. Renal disease in the elderly. Nephron 1998;80(1):6- 16(Pubitemid 28434686)